Until recently, progress in the management of cervical cancer had been slow, resulting in a 5-year survival rate of just 16.5% for advanced/metastatic disease. Recent FDA approvals have led to a paradigm shift in treatment of this devastating disease, but the swift emergence of novel agents has meant that healthcare professionals may not be familiar with use of new therapies in clinical practice or the prevention and management of their associated toxicities.

In this interactive, on-demand, multimedia educational activity, gynecologic oncology experts present key evidence in support of novel treatments to manage advanced and recurrent cervical cancer, including discussion of patient cases and recommendations on managing adverse events (AEs) associated with novel therapies. Three ClinicalThought commentaries cover a day in the life of an APP treating cervical cancer, FAQs, and an ophthalmologist’s commentary on managing novel therapy-associated AEs. In addition, a patient resource on appropriate eye care in patients receiving tisotumab vedotin is available to download and share.

Downloadable Patient Resource:

Ocular Toxicity Associated With Antibody-Drug Conjugates in Gynecologic Cancers: A Patient Resource

Faculty

Maria Avila-Wallace, NPNurse PractitionerDivision of Gynecologic Oncology Department of Obstetrics and Gynecology Massachusetts General Hospital Boston, Massachusetts

Grace Mbyirukira, MPAS, PA-C Physician AssistantDivision of Gynecologic Oncology Department of Obstetrics and Gynecology Parkland Health and Hospital System Dallas, Texas

Lauren Prescott, MD Assistant ProfessorDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyVanderbilt University Medical CenterNashville, Tennessee